Skip to main content

Further GMP expansion in peptides for CordenPharma

CordenPharma has announced the approval of a long-term expansion initiative “to further increase our flexibility, efficiency and ultimately, cost-effective production” at its solid-phase peptide synthesis (SPPS) in Boulder, Colorado. This follows the installation of an extra-large 3,000L SPPS vessel at the site earlier this year in response to growing demand for peptide APIs.

CordenPharma further expands peptides

CordenPharma is to expand non-GMP solid-phase peptide synthesis (SPPS) capacity at its centre of excellence for peptide process development and non-GMP manufacturing at Frankfurt, Germany. This should be complete in Q3 2021. The amount invested has not been disclosed.

The investment will increase lab space by 25% and add a dedicated explosionproof area. The latter will be supported by a tank farm, which, the company said, “will allow for the introduction of regular solvents, as well as compatibility with our green peptide manufacturing”.

More CDMOs in COVID-19 deals

The ongoing race to develop the first effective vaccines for the treatment of COVID-19 continues to generate manufacturing and development agreements between pharmaceutical giants, biotechs and CDMOs.

Most recently, Sterling Pharma Solutions agreed to carry out final purification of drug product for Moleculin Biotech’s WP1122 drug candidate from its site in Cary, North Carolina. Moleculin is about to submit an IND for this to the FDA and wanted a reliable source of supply in the US.

CordenPharma in peptide expansion

CordenPharma has announced the addition of a 3,000-litre solid-phase peptide synthesis (SPPS) vessel at its GMP API facility in Boulder, Colorado. This site, which was formerly owned by Roche, already has a 10,000-litre SPPS vessel and a 100 cm high-pressure reverse phase purification column, and is claimed to have the largest capacity of any peptide API facility.

Change at the top for CDMOs

Two of the major global pharmaceutical CDMOs, Lonza and Alcami, have announced the appointments of new CEOs in early June. There have also been changes in senior positions at Corden Pharma and, imminently, at Cambrex.

Subscribe to CordenPharma

 

SC newsletter banner